Syensqo (SYENS) investor relations material

Executive summary

• Net sales reached EUR 1.4 billion in Q1 2026, up 5% sequentially but down 7% year-over-year, with growth led by Specialty Polymers and Novecare; volumes were stable year-on-year.

• Underlying EBITDA was EUR 251 million (17.9% margin), up 6.5% sequentially but down 17% year-over-year.

• Gross margin was resilient at 31.7%, up 260 bps sequentially but down 110 bps year-over-year.

• The sale of the Oil & Gas business was completed in January, generating EUR 130 million in net proceeds.

• Leadership changes and targeted programs were launched to accelerate growth and address underperformance.

Financial highlights

• Net sales of EUR 1.4 billion, up 5% sequentially but down 7.4% year-over-year; underlying EBITDA of EUR 251 million, up 6% sequentially but down 17% year-over-year.

• Gross profit for Q1 2026 was EUR 444 million, gross margin 31.7%, up 260 bps sequentially.

• Operating cash flow was EUR 82 million in Q1, impacted by working capital and project costs; full-year operating cash flow expected at EUR 700 million.

• CapEx for the quarter was EUR 97 million, down 44% year-over-year; full-year CapEx outlook reduced by up to EUR 50 million to EUR 450 million.

• Net debt at EUR 2.0 billion, gearing ratio 24%, leverage ratio 1.7x; EUR 500 million bond redeemed.

Outlook and guidance

• Full-year 2026 underlying EBITDA and operating cash flow outlook remain unchanged at approximately EUR 1.1 billion and EUR 700 million, with Q1 expected to be the lowest quarter.

• Gradual recovery in volumes anticipated through the year, especially in Composite Materials and Electronics.

• Capital expenditure guidance lowered to EUR 450 million for 2026.

• Sequential improvement in Q2 and further step-up in Q3 expected to meet full-year guidance.

• Impact from Middle East conflict expected to be limited, with mitigation actions in place.